Logo image of XAGE

LONGEVITY HEALTH HOLDINGS IN (XAGE) Stock Fundamental Analysis

NASDAQ:XAGE - Nasdaq - US1429221039 - Common Stock - Currency: USD

2.38  -1.07 (-31.01%)

After market: 2.32 -0.06 (-2.52%)

Fundamental Rating

0

Taking everything into account, XAGE scores 0 out of 10 in our fundamental rating. XAGE was compared to 562 industry peers in the Biotechnology industry. Both the profitability and financial health of XAGE have multiple concerns. XAGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XAGE has reported negative net income.
XAGE had a negative operating cash flow in the past year.
In the past 5 years XAGE reported 4 times negative net income.
In the past 5 years XAGE always reported negative operating cash flow.
XAGE Yearly Net Income VS EBIT VS OCF VS FCFXAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

XAGE has a Return On Assets of -703.41%. This is amonst the worse of the industry: XAGE underperforms 97.69% of its industry peers.
Industry RankSector Rank
ROA -703.41%
ROE N/A
ROIC N/A
ROA(3y)-242.83%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XAGE Yearly ROA, ROE, ROICXAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

XAGE has a Gross Margin of 87.48%. This is amongst the best in the industry. XAGE outperforms 89.68% of its industry peers.
XAGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XAGE Yearly Profit, Operating, Gross MarginsXAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

XAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
XAGE has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, XAGE has a worse debt to assets ratio.
XAGE Yearly Shares OutstandingXAGE Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
XAGE Yearly Total Debt VS Total AssetsXAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -80.35, we must say that XAGE is in the distress zone and has some risk of bankruptcy.
XAGE's Altman-Z score of -80.35 is on the low side compared to the rest of the industry. XAGE is outperformed by 95.91% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -80.35
ROIC/WACCN/A
WACC9.99%
XAGE Yearly LT Debt VS Equity VS FCFXAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.16 indicates that XAGE may have some problems paying its short term obligations.
The Current ratio of XAGE (0.16) is worse than 96.80% of its industry peers.
A Quick Ratio of 0.14 indicates that XAGE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.14, XAGE is doing worse than 96.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.14
XAGE Yearly Current Assets VS Current LiabilitesXAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

XAGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.02%, which is quite impressive.
Looking at the last year, XAGE shows a very negative growth in Revenue. The Revenue has decreased by -98.65% in the last year.
EPS 1Y (TTM)74.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.01%
Revenue 1Y (TTM)-98.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XAGE Yearly Revenue VS EstimatesXAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 10K 20K 30K 40K 50K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XAGE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XAGE Price Earnings VS Forward Price EarningsXAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XAGE Per share dataXAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XAGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LONGEVITY HEALTH HOLDINGS IN

NASDAQ:XAGE (5/23/2025, 9:04:16 PM)

After market: 2.32 -0.06 (-2.52%)

2.38

-1.07 (-31.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners8.88%
Inst Owner ChangeN/A
Ins Owners11.63%
Ins Owner ChangeN/A
Market Cap2.38M
AnalystsN/A
Price TargetN/A
Short Float %1.82%
Short Ratio0.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 47.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.39
FCFYN/A
OCF(TTM)-4.39
OCFYN/A
SpS0.05
BVpS-4.71
TBVpS-4.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -703.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.48%
FCFM N/A
ROA(3y)-242.83%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.14
Altman-Z -80.35
F-Score2
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.01%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.43%
OCF growth 3YN/A
OCF growth 5YN/A